Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS-833923 (XL-139), an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $46 | In Stock | |
| 10 mg | $74 | In Stock | |
| 25 mg | $129 | In Stock | |
| 50 mg | $208 | In Stock | |
| 100 mg | $376 | In Stock | |
| 200 mg | $553 | In Stock | |
| 500 mg | $878 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $54 | In Stock |
| Description | BMS-833923 (XL-139), an orally bioavailable Smoothened antagonist, inhibits BODIPY cyclopamine binding to SMO in a dose-dependent manner (IC50: 21 nM). |
| Targets&IC50 | BODIPY:21 nM |
| In vivo | BMS-833923 dose-dependently affected the transcription of prostate hedgehog signaling genes in vitro.BMS-833923 caused a decrease in hedgehog pathway activity, reduced cell proliferation, and induced apoptosis in esophageal adenocarcinoma cell lines via an endogenous pathway. |
| Synonyms | XL-139 |
| Molecular Weight | 473.57 |
| Formula | C30H27N5O |
| Cas No. | 1059734-66-5 |
| Smiles | CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1 |
| Relative Density. | 1.252 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 88 mg/mL (185.82 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.97 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.